Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 23s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

The Potential Therapeutic Role of EGCG (Epigallocatechin-3-Gallate) in Diabetes Progression

Akash Koley[1], Dr. Pallavi Tiwari[2], V S S S Gupta Atyam[3], Devender Sharma[4], Ayan Mukherjee[5], Dr. Neeli Rose Beck[6], Dr G. Chandra Shekhara Rao[7], Dr. M. Vijaya Jyothi[8*]

[1]Assistant Professor, Department of Pharmacology, Calcutta Institute of Pharmaceutical Technology & Allied Health Sciences

Email ID: akash93koley@gmail.com

[2]Associate professor, United Institute of Pharmacy, Naini, Prayagraj

Email ID: pallavitiwari25@gmail.com

[3]Associate Professor, Department Of Pharmacology, Joginpally B.R. Pharmacy College

Email ID: guptaatyam@gmail.com

[4]Assistant Professor, R J world college of Pharmacy Education and Technology, Jakhod Surajgarh Jhunjhunu Rajasthan 333033

Email ID: sdevender350@gmail.com

[5]Assistant Professor, Department of Pharmacology, Calcutta Institute of Pharmaceutical Technology & Allied Health Sciences

Email ID: ayan7112002@gmail.com

[6]Associate Professor, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur, CG

Email ID: neeli05011974@gmail.com

[7]Vignan Institute of Pharmaceutical Technology, Duvvada, Visakhapatnam

Email ID: gonuguntac2@gmail.com

[8*]Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, AP

Email ID: drmvjyothiriper@gmail.com

***Corresponding Author**

Dr. M. Vijaya Jyothi,

Professor, Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, AP

Email ID: drmvjyothiriper@gmail.com

Cite this paper as: Akash Koley, Dr. Pallavi Tiwari, V S S S Gupta Atyam, Devender Sharma, Ayan Mukherjee, Dr. Neeli Rose Beck, Dr G. Chandra Shekhara Rao, Dr. M. Vijaya Jyothi, (2025) The Potential Therapeutic Role of EGCG (Epigallocatechin-3-Gallate) in Diabetes Progression. *Journal of Neonatal Surgery*, 14 (23s), 8-16

ABSTRACT

Diabetes mellitus is a complex and widespread metabolic disorder that continues to pose significant health challenges worldwide. While existing treatments help manage blood sugar levels, they often fail to fully address the underlying causes and long-term complications of the disease. Epigallocatechin-3-gallate (EGCG), a powerful antioxidant found in green tea, has attracted growing interest for its potential role in slowing diabetes progression. Research suggests that EGCG may help improve insulin sensitivity, protect pancreatic β-cells, reduce inflammation, and regulate glucose metabolism—factors that are central to both Type 1 and Type 2 diabetes. It also interacts with key cellular pathways, including AMPK, PI3K/Akt, and NF-κB, which are involved in maintaining metabolic balance. Studies in animal models and early clinical trials have shown promising results, but challenges such as low bioavailability and limited long-term human data remain. New approaches like nanoformulations are being explored to improve how EGCG is absorbed and used in the body. Overall, EGCG shows promise as a supportive therapy for diabetes, though more rigorous human studies are needed to better understand its full potential and ensure its safe use.

1. INTRODUCTION

Diabetes mellitus is a chronic metabolic disorder that affects how the body regulates blood sugar (glucose). It primarily

manifests in two major forms: Type 1 and Type 2. Type 1 diabetes is an autoimmune condition where the body's immune system attacks insulin-producing β-cells in the pancreas, leading to little or no insulin production.[1] It typically develops in childhood or adolescence but can occur at any age. In contrast, Type 2 diabetes, which accounts for the vast majority of cases, is characterized by insulin resistance and a gradual decline in β-cell function. It is closely associated with lifestyle factors such as poor diet, physical inactivity, and obesity. [2] Diabetes is characterized by elevated blood sugar levels, which, over time, can lead to severe damage to the heart, blood vessels, eyes, kidneys, and nerves. [3] Over the past few decades, the global burden of diabetes has risen dramatically. According to the International Diabetes Federation, over 530 million adults worldwide were living with diabetes in 2021, and this number is expected to rise significantly in the coming years. The disease not only reduces quality of life but also increases the risk of serious complications such as cardiovascular disease, kidney failure, neuropathy, and retinopathy. These complications contribute to increased healthcare costs and place a substantial burden on healthcare systems globally.[4] The prevalence of diabetes mellitus has become a major global public health concern, particularly in developing nations, where its incidence is rapidly increasing.[5] Given the limitations of current treatments—which largely focus on controlling blood glucose rather than addressing the broader mechanisms driving the disease—there is growing interest. Diabetes mellitus is a chronic metabolic disorder that affects how the body regulates blood sugar (glucose). It primarily manifests in two major forms: Type 1 and Tyrnative and complementary therapies. One such compound that has drawn scientific attention is epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea. [6] EGCG is well known for its potent antioxidant and anti-inflammatory properties, and it has been studied for a wide range of health benefits, including cardiovascular protection, anti-cancer effects, and neuroprotection. More recently, its potential role in metabolic diseases such as diabetes has emerged as a promising area of research. EGCG has been shown to influence insulin activity, reduce oxidative stress, and modulate several signaling pathways involved in glucose and lipid metabolism, suggesting it could play a meaningful role in diabetes management and the prevention of its progression. [7] The rising prevalence of diabetes is largely attributed to the rapid spread of obesity, making it the most significant risk factor for type 2 diabetes mellitus. [8] EGCG, a green tea polyphenol, has emerged as a promising candidate for mitigating macrovascular complications associated with diabetes, an area of increasing global concern [9,10]

This review explores the therapeutic potential of EGCG in diabetes by examining its biological effects, the mechanisms through which it may act, and the current evidence from both preclinical and clinical studies. It also considers the challenges associated with its use and potential strategies to enhance its effectiveness as a supportive treatment option..

Biochemistry and Pharmacokinetics of EGCG

Epigallocatechin-3-gallate (EGCG) is the most abundant and biologically active catechin found in green tea (Camellia sinensis). Structurally, EGCG belongs to the flavonoid group of polyphenols and is characterized by a gallate group esterified at the 3-position of the flavan-3-ol epigallocatechin. This molecular structure contributes significantly to its strong antioxidant properties, allowing it to scavenge free radicals and chelate metal ions, which can be particularly beneficial in combating oxidative stress, a major contributor to diabetes-related tissue damage. The bioavailability of EGCG, however, is a critical factor affecting its therapeutic efficacy. [11]

Despite its promising bioactivity, the therapeutic application of EGCG is limited by its pharmacokinetic profile. After oral administration, EGCG undergoes extensive metabolism in the intestines and liver. It is absorbed primarily in the small intestine through passive diffusion and active transport mechanisms. Once absorbed, it undergoes phase II metabolism, including methylation, glucuronidation, and sulfation, processes that significantly alter its biological activity and reduce its effective concentration in systemic circulation.[12]

Moreover, EGCG has relatively low bioavailability. Studies have shown that only a small fraction of the ingested compound reaches the bloodstream in its active form, and it is rapidly eliminated through the urine and bile. Factors such as pH sensitivity, poor membrane permeability, and degradation in the gastrointestinal tract further reduce its absorption. Additionally, EGCG is known to bind to proteins and lipids in the digestive system, which can also interfere with its bioavailability. To improve its bioavailability, various strategies have been explored, including encapsulation in liposomes or nanoparticles, co-administration with piperine (a bioavailability enhancer), and structural modifications to enhance its stability and permeability [7,13]

To address these limitations, researchers have been exploring various strategies to enhance EGCG's stability and absorption. These include the use of nanoparticle delivery systems, liposomes, phospholipid complexes, and structural modifications. Co-administration with other compounds, such as ascorbic acid or piperine, has also shown potential to improve EGCG's bioavailability. Such innovations are essential for translating the promising in vitro and animal model results into effective human therapies. Liposomal formulations, micelles, and nanoparticles are being investigated as delivery modalities to improve the therapeutic potential of chlorogenic acid by increasing its stability, bioactivity, and bioavailability. [14,15]

Understanding the biochemical nature and pharmacokinetic challenges of EGCG is crucial for optimizing its therapeutic potential. A deeper knowledge of how EGCG is metabolized and interacts within the body lays the groundwork for developing more effective formulations and dosing strategies that could be used to target chronic diseases like diabetes. It is crucial to take into account the complexity of in vivo metabolic activity and biotransformation when interpreting in vitro

results and applying them to human physiopathology. [16]

Biochemistry and Pharmacokinetics of EGCG

Structure and Properties of EGCG

Epigallocatechin-3-gallate (EGCG) is the most active and widely studied catechin found in green tea (Camellia sinensis). As a polyphenol, EGCG belongs to the flavonoid family and is recognized for its strong antioxidant capabilities. Structurally, it contains multiple hydroxyl groups and a distinctive gallate group attached to its core flavanol skeleton. These chemical features are responsible for EGCG's ability to neutralize harmful free radicals and interact with various biological molecules, including proteins and lipids. [17] The bioavailability and stability of EGCG can be greatly impacted by its sensitivity to environmental factors such as pH, temperature, and the presence of enzymes or other compounds.

Thanks to its antioxidant and anti-inflammatory properties, EGCG has been explored for its effects in a wide range of diseases. In the context of diabetes, its ability to influence glucose metabolism and reduce oxidative stress makes it particularly intriguing as a potential therapeutic compound. [13]

EGCG also possesses antimicrobial qualities, which may have an impact on the gut microbiota, which in turn may affect glucose homeostasis and general metabolic health. [18]

Absorption, Metabolism, and Bioavailability

While EGCG has shown great promise in laboratory studies, one of the main hurdles to its clinical use is its poor bioavailability. After being consumed, only a small portion of EGCG is absorbed in the gut. Much of it is either broken down or transformed before it can reach the bloodstream in its active form. Once inside the body, EGCG is quickly metabolized—mostly in the liver—where it undergoes chemical changes such as methylation, glucuronidation, and sulfation. These changes can reduce its biological activity and effectiveness. [19]

Even when it does enter the bloodstream, EGCG doesn't stay there long. Its half-life is relatively short, usually just a few hours, and it is rapidly eliminated through urine or bile. Additionally, EGCG is chemically unstable in the digestive tract, especially at neutral or alkaline pH levels, and it can degrade before having any significant effect.

Challenges in Clinical Use

Several practical issues limit how well EGCG works when taken as a supplement:

Instability: EGCG is sensitive to heat, light, and pH changes, which can lead to its breakdown before it becomes useful in the body.

Poor Absorption: It doesn't pass easily through cell membranes, limiting how much of it gets into tissues where it's needed.

Rapid Metabolism: The body transforms EGCG into less active forms quite quickly, limiting its overall impact. Binding to Other Molecules: In the digestive system and bloodstream, EGCG can bind to proteins and fats, reducing how much is available in its free, active form.

To address these limitations, researchers have been developing more advanced ways to deliver EGCG. These include using nanoparticles, liposomes, and other encapsulation techniques that protect the molecule and help it reach its target more effectively. Some studies have also looked at combining EGCG with compounds like vitamin C or black pepper extract to improve absorption and prolong its activity in the body.

Overall, while EGCG's natural properties are promising, especially for managing diseases like diabetes, improving how it's delivered and absorbed remains a key step toward making it a reliable treatment option. [11]

Mechanisms of Action Relevant to Diabetes

The growing interest in EGCG as a therapeutic agent for diabetes stems from its ability to interact with multiple biological pathways involved in the development and progression of the disease. Diabetes, particularly Type 2, is driven by a combination of insulin resistance, chronic inflammation, oxidative stress, and impaired pancreatic β-cell function. EGCG appears to influence each of these factors in a beneficial way, making it a compelling candidate for further investigation. [20]

Antioxidant and Anti-inflammatory Activity

One of EGCG's most well-documented properties is its antioxidant capacity. By neutralizing reactive oxygen species (ROS), EGCG helps reduce oxidative stress, which is a known contributor to β-cell damage and insulin resistance. In diabetic individuals, excessive ROS production can impair insulin signaling and lead to complications like neuropathy, retinopathy, and kidney damage. EGCG not only scavenges free radicals directly but also supports the activity of endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase. [21]

In addition to its antioxidant effects, EGCG has been shown to have strong anti-inflammatory properties. It downregulates the expression of inflammatory cytokines such as TNF-α, IL-6, and CRP—molecules that are often elevated in people with

insulin resistance. EGCG can also inhibit activation of NF-κB, a key transcription factor involved in the inflammatory response. By curbing chronic inflammation, EGCG may help preserve insulin sensitivity and protect tissues from damage. [13]

Enhancement of Insulin Sensitivity and Glucose Uptake

EGCG has shown potential to improve the way the body responds to insulin. It does this by enhancing insulin signaling pathways, particularly through activation of the AMP-activated protein kinase (AMPK) pathway. AMPK is a cellular energy sensor that plays a central role in regulating glucose and lipid metabolism. When activated, AMPK promotes glucose uptake in skeletal muscle and suppresses the production of glucose in the liver—two key mechanisms that help lower blood sugar levels. [22]

Some studies have also demonstrated that EGCG enhances the translocation of glucose transporter type 4 (GLUT4) to the cell surface in muscle and fat cells, thereby increasing glucose uptake in response to insulin. These effects may help counteract the insulin resistance that characterizes Type 2 diabetes.

[23]

Protection and Regeneration of Pancreatic β-Cells

In Type 1 diabetes and the later stages of Type 2, the progressive loss of pancreatic β-cells compromises the body's ability to produce insulin. EGCG has been found to protect β-cells from damage caused by oxidative stress and inflammatory insults. It may also help maintain β-cell function by preserving mitochondrial integrity and preventing apoptosis (programmed cell death). Although the evidence is still emerging, there are also indications that EGCG might support β-cell regeneration, particularly in the presence of a supportive cellular environment. [24]

Modulation of Key Signaling Pathways

Beyond AMPK, EGCG affects several other signaling pathways involved in glucose and lipid metabolism. For example, it influences the PI3K/Akt pathway, which is crucial for insulin signal transduction. EGCG also modulates pathways like MAPK and JNK, which are often dysregulated in metabolic disorders. By influencing these pathways, EGCG can reduce insulin resistance and improve cellular responses to insulin.[25]

Preclinical Evidence Supporting EGCG in Diabetes Management

A substantial body of preclinical research—including in vitro studies and animal models—has provided strong support for the potential role of EGCG in managing diabetes and its complications. These studies have not only highlighted its glucose-lowering effects but also shed light on how EGCG modulates various biological systems involved in the disease process. [26]

In Vitro Studies

In laboratory experiments using cultured cells, EGCG has demonstrated multiple anti-diabetic actions. For example, studies on insulin-resistant hepatocytes and adipocytes have shown that EGCG enhances glucose uptake by stimulating insulin signaling and increasing the expression of glucose transporter proteins like GLUT4. In pancreatic β-cell lines, EGCG has been observed to protect against oxidative damage, preserve mitochondrial function, and reduce apoptosis—all of which support healthy insulin secretion.

Moreover, EGCG has been found to suppress the activity of enzymes involved in glucose production, such as glucose-6-phosphatase, and inhibit advanced glycation end-product (AGE) formation. AGEs contribute to many of the long-term complications of diabetes, including cardiovascular disease and kidney dysfunction. By interfering with this process, EGCG may offer protective benefits beyond glycemic control. [27]

Animal Studies

Animal models of both Type 1 and Type 2 diabetes have provided further insight into EGCG's therapeutic potential. In diet-induced obese and insulin-resistant mice, EGCG supplementation has consistently led to improvements in fasting blood glucose levels, insulin sensitivity, and lipid profiles. These changes are often accompanied by reductions in systemic inflammation and oxidative stress markers.

In Type 1 diabetes models, such as streptozotocin (STZ)-induced diabetic rats, EGCG has shown protective effects on pancreatic islets and appears to mitigate the autoimmune destruction of β-cells to some extent. Additionally, EGCG has been reported to improve glucose tolerance, reduce hyperglycemia-induced tissue damage, and prevent diabetic complications like nephropathy and retinopathy in long-term studies.

Mechanistically, animal studies have confirmed EGCG's role in activating the AMPK pathway, reducing NF-κB activity, and improving mitochondrial function in tissues affected by diabetes. Its impact on lipid metabolism—such as reducing hepatic lipid accumulation and improving cholesterol levels—also contributes to its beneficial metabolic profile. Research has demonstrated that EGCG is involved in regulating various metabolic processes and has been employed as an anti-obesity

agent in both animal models and human trials, demonstrating its potential as a therapeutic agent. [28]

Dosage and Safety in Preclinical Models

In most preclinical studies, EGCG has been administered in doses ranging from 25 to 100 mg/kg/day, usually through oral gavage or dietary inclusion. These studies have generally reported favorable safety profiles, though extremely high doses have occasionally been linked to liver toxicity. This underlines the importance of dose optimization and careful monitoring when considering translation to human use. [29]

Clinical Evidence and Human Trials

While preclinical studies provide a strong foundation for understanding the potential of EGCG in diabetes management, clinical research in human subjects is essential to validate its therapeutic relevance. Over the past decade, a growing number of clinical trials and observational studies have evaluated the effects of EGCG—either as a pure compound or as a component of green tea—on glycemic control, insulin sensitivity, and related metabolic outcomes in people with or at risk for diabetes.

[26]

Effects on Glycemic Control

Several human studies have examined EGCG's ability to regulate blood glucose levels. In randomized controlled trials (RCTs), daily supplementation with EGCG or green tea extract has been associated with modest reductions in fasting blood glucose and hemoglobin A1c (HbA1c) in patients with Type 2 diabetes or prediabetes. One study involving overweight individuals with insulin resistance found that 300 mg/day of EGCG for 12 weeks significantly improved fasting glucose and insulin sensitivity, as measured by HOMA-IR scores. [30]

However, results across trials have been somewhat variable, with some studies reporting no significant changes in glucose metabolism. Differences in study design, dosage, treatment duration, and baseline metabolic status of participants likely contribute to these inconsistencies. Nonetheless, the overall trend in the data supports the notion that EGCG may offer glycemic benefits, particularly when used as an adjunct to lifestyle changes or conventional medications. [31]

Impact on Insulin Sensitivity and Lipid Profile

Beyond glucose control, EGCG appears to have favorable effects on other metabolic markers relevant to diabetes. Several trials have reported improvements in insulin sensitivity and reductions in serum insulin levels following EGCG supplementation. These effects may be partly mediated by enhanced insulin signaling and reduced systemic inflammation, as suggested by decreases in biomarkers such as C-reactive protein (CRP) and interleukin-6 (IL-6).

Additionally, EGCG has been shown to improve lipid profiles by lowering total cholesterol, LDL cholesterol, and triglycerides in both diabetic and non-diabetic individuals. These changes are particularly meaningful, given the high cardiovascular risk associated with diabetes. [28]

Effects on Weight and Body Composition

Weight loss and improved body composition can significantly enhance insulin sensitivity and glycemic control. Some studies have found that EGCG, particularly when combined with caffeine or other catechins, promotes modest weight loss and reductions in waist circumference. The proposed mechanisms include increased fat oxidation, thermogenesis, and modulation of appetite-regulating hormones. Although the magnitude of weight loss is generally modest, it may still contribute meaningfully to overall metabolic improvements in individuals with diabetes or metabolic syndrome. [32]

Safety and Tolerability in Humans

In clinical settings, EGCG has generally been well tolerated at doses up to 800 mg/day. Reported side effects are typically mild and include gastrointestinal symptoms such as nausea or stomach upset. However, rare cases of liver enzyme elevations and hepatotoxicity have been reported, especially with high doses or concentrated green tea extracts taken on an empty stomach. As such, careful dosing and monitoring are recommended in clinical use, particularly for individuals with existing liver conditions.

Overall, while the clinical evidence is still evolving, current data suggest that EGCG may offer supportive benefits for people with diabetes—particularly in improving glucose regulation, insulin sensitivity, and lipid profiles. Larger, well-controlled trials with standardized dosing protocols are needed to confirm its efficacy and establish optimal therapeutic regimens. [33]

Challenges, Limitations, and Future Directions

Despite the promising results from both preclinical and clinical studies, several challenges remain in translating EGCG's therapeutic potential into a widely applicable treatment for diabetes. These challenges are related to both the bioavailability of EGCG and the variability in clinical outcomes. Furthermore, understanding the long-term safety and effectiveness of EGCG, as well as identifying the most appropriate patient populations for its use, is essential for its broader application in diabetes management.

Challenges in EGCG Bioavailability and Delivery

One of the most significant hurdles in the clinical use of EGCG is its poor bioavailability. As discussed earlier, EGCG is poorly absorbed in the gastrointestinal tract, undergoes rapid metabolism in the liver, and has a short half-life in the bloodstream. These factors greatly limit the amount of EGCG that reaches the target tissues in a pharmacologically active form.

To overcome these limitations, researchers are exploring various strategies for improving the bioavailability of EGCG. These include the development of novel delivery systems, such as nanoparticles, liposomes, and microencapsulation, that protect the compound from degradation and facilitate its absorption. Additionally, combining EGCG with absorption enhancers like piperine (from black pepper) or ascorbic acid (vitamin C) may help increase its bioavailability. Another promising approach is the synthesis of EGCG analogs or prodrugs designed to have better stability and absorption profiles. [34]

Variability in Clinical Outcomes

While numerous clinical trials have shown positive effects of EGCG supplementation on blood glucose levels, insulin sensitivity, and other metabolic markers, the results across studies have not been entirely consistent. Factors such as differences in study design, participant characteristics (e.g., baseline metabolic status, age, gender), dosage, and the duration of supplementation likely contribute to this variability. Moreover, some studies have used green tea extract rather than isolated EGCG, which contains other polyphenols that may influence the results.

Given these inconsistencies, it is important to establish standardized protocols for EGCG supplementation in future trials, including optimal dosages, treatment regimens, and patient selection criteria. This will help determine whether EGCG should be used as an adjunctive therapy for diabetes, and if so, in which specific patient populations it would be most beneficial. [35]

Long-Term Safety and Efficacy

While EGCG appears to be safe at moderate doses, concerns about potential hepatotoxicity, especially with high doses or long-term use, have been raised in both animal models and human trials. Although rare, cases of liver damage have been reported, particularly with the use of concentrated green tea extracts. This highlights the need for further investigation into the long-term safety profile of EGCG, especially in individuals with pre-existing liver conditions.

Future research should include large-scale, long-term clinical trials to evaluate the safety and efficacy of EGCG in various populations, including those with different stages of diabetes and those at high risk for developing the disease. Additionally, these trials should explore the potential synergistic effects of EGCG when combined with other therapies or lifestyle interventions, such as diet and exercise. [36]

Future Directions

Despite the challenges, there are several exciting directions for future research on EGCG and its role in diabetes management:

Personalized Medicine: Given the variability in clinical outcomes, there is an opportunity to tailor EGCG therapy to individual patients based on their genetic makeup, metabolic profile, and coexisting conditions. For example, certain genetic polymorphisms might influence how individuals metabolize EGCG, affecting its efficacy and safety.

Combination Therapies: EGCG may work synergistically with other anti-diabetic drugs, such as metformin or GLP-1 receptor agonists. Investigating these combination therapies could provide a more comprehensive approach to managing diabetes and its complications. [37]

Exploring EGCG’s Impact on Diabetes Complications: While much of the focus has been on glycemic control, there is growing interest in EGCG’s potential to prevent or treat diabetes-related complications, such as diabetic retinopathy, nephropathy, and neuropathy. Long-term studies are needed to explore these benefits in greater depth.

Improved Formulations: Advances in drug delivery technologies, such as targeted nanoparticle systems or sustained-release formulations, hold great promise for improving the bioavailability and clinical efficacy of EGCG. The development of more efficient delivery systems will likely play a critical role in enhancing the therapeutic potential of EGCG in diabetes. [38]

2. CONCLUSION

EGCG, the principal polyphenol in green tea, has shown significant promise as a therapeutic agent in the management of diabetes. Through its antioxidant, anti-inflammatory, and insulin-sensitizing effects, EGCG may help address several of the underlying mechanisms of the disease, including oxidative stress, insulin resistance, and β-cell dysfunction. Preclinical and clinical evidence suggests that EGCG supplementation can improve glycemic control, insulin sensitivity, and lipid metabolism in individuals with diabetes. However, challenges related to its bioavailability, inconsistent clinical results, and concerns about long-term safety must be addressed before EGCG can become a mainstream therapeutic option for diabetes.

Future research should focus on optimizing delivery methods, standardizing treatment protocols, and exploring combination

therapies. With continued investigation into its mechanisms and long-term effects, EGCG holds the potential to play an important role in the prevention and treatment of diabetes, especially when used as part of a comprehensive management strategy that includes diet, exercise, and pharmacological therapies

REFERENCES

[1] Jiao H, Xiao E, Graves DT. Diabetes and Its Effect on Bone and Fracture Healing. Current Osteoporosis Reports [Internet]. Springer Science+Business Media; 2015 Aug 8 [cited 2025 Apr];13(5):327. Available from: https://doi.org/10.1007/s11914-015-0286-8

[2] Valaiyapathi B, Gower BA, Ashraf AP. Pathophysiology of Type 2 Diabetes in Children and Adolescents. Current Diabetes Reviews [Internet]. Bentham Science Publishers; 2019 Feb 1 [cited 2025 Apr];16(3):220. Available from: https://doi.org/10.2174/1573399814666180608074510

[3] Thapa S, Kayastha P, Mishra DK. Assessment of Risk of Type 2 Diabetes Among Adults of Banepa Municipality, Nepal: Community Based Cross-Sectional Study. International Journal of Travel Medicine and Global Health [Internet]. 2020 Mar 9 [cited 2025 Feb];8(1):31. Available from: https://doi.org/10.34172/ijtmgh.2020.05

[4] Kitada M, Zhang Z, Mima A, King GL. Molecular mechanisms of diabetic vascular complications. Journal of Diabetes Investigation [Internet]. Asian Association for the Study of Diabetes; 2010 Mar 22 [cited 2025 Apr];1(3):77. Available from: https://doi.org/10.1111/j.2040-1124.2010.00018.x

[5] Glen E, Nadro MS, Yaduma WG, Agbo EB. Exploring the ameliorating potentials of Phyllanthus fraternus methanolic leaf extract on hepatic and renal dysfunctions in diabetic rats. African Journal of Biological Sciences [Internet]. 2022 Oct 5 [cited 2025 Mar];4(4):70. Available from: https://doi.org/10.33472/afjbs.4.4.2022.70-76

[6] Zuo X, Tian C, Zhao N, Ren W, Yi M, Jin X, Zhang Y, Ding S, Ying C, Ye X. Tea polyphenols alleviate high fat and high glucose-induced endothelial hyperpermeability by attenuating ROS production via NADPH oxidase pathway. BMC Research Notes [Internet]. 2014 Mar 2 [cited 2025 Feb];7(1). Available from: https://doi.org/10.1186/1756-0500-7-120

[7] Potenza MA, Iacobazzi D, Sgarra L, Montagnani M. The Intrinsic Virtues of EGCG, an Extremely Good Cell Guardian, on Prevention and Treatment of Diabesity Complications. Molecules [Internet]. Multidisciplinary Digital Publishing Institute; 2020 Jul 4 [cited 2025 Apr];25(13):3061. Available from: https://doi.org/10.3390/molecules25133061

[8] Wolfram S, Raederstorff D, Preller M, Wang Y, Teixeira SR, Riegger C, Weber P. Epigallocatechin Gallate Supplementation Alleviates Diabetes in Rodents. Journal of Nutrition [Internet]. 2006 Oct 1 [cited 2025 Mar];136(10):2512. Available from: https://doi.org/10.1093/jn/136.10.2512

[9] Tang L, Li L, Yang J, Zeng C. Potential benefit of (-)-epigallocatechin-3-gallate for macrovascular complications in diabetes. Brazilian Journal of Medical and Biological Research [Internet]. 2017 Jan 1 [cited 2025 Apr];50(10). Available from: https://doi.org/10.1590/1414-431x20176511

[10] Rashid A. Untitled [Internet]. 2024 Mar [cited 2025 Apr]. Available from: https://doi.org/10.55277/researchhub.vq5dnd6h

[11] Gan L, Meng Z, Xiong R, Guo J, Xiao-cui L, Zheng Z wei, Deng Y, Luo B, Zou F, Li H. Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice. Acta Pharmacologica Sinica [Internet]. 2015 Apr 20 [cited 2025 Apr];36(5):597. Available from: https://doi.org/10.1038/aps.2015.11

[12] Sanchez RI, Kauffman FC. Regulation of Xenobiotic Metabolism in the Liver. In: Elsevier eBooks [Internet]. Elsevier BV; 2010 [cited 2025 Feb]. p. 109. Available from: https://doi.org/10.1016/b978-0-08-046884-6.01005-8

[13] Mokrá D, Jošková M, Mokrý J. Therapeutic Effects of Green Tea Polyphenol (–)-Epigallocatechin-3-Gallate (EGCG) in Relation to Molecular Pathways Controlling Inflammation, Oxidative Stress, and Apoptosis. International Journal of Molecular Sciences [Internet]. Multidisciplinary Digital Publishing Institute; 2022 Dec 25 [cited 2025 Apr];24(1):340. Available from: https://doi.org/10.3390/ijms24010340

[14] Laudadio E, Minnelli C, Amici A, Massaccesi L, Mobbili G, Galeazzi R. Liposomal Formulations for an Efficient Encapsulation of Epigallocatechin-3-Gallate: An In-Silico/Experimental Approach. Molecules [Internet]. 2018 Feb 16 [cited 2025 Apr];23(2):441. Available from: https://doi.org/10.3390/molecules23020441

[15] Huang J, Ming-xiang X, He L, Song X, Cao T. Chlorogenic acid: a review on its mechanisms of anti-inflammation, disease treatment, and related delivery systems. Frontiers in Pharmacology [Internet]. Frontiers

Media; 2023 Sep 13 [cited 2025 Apr];14. Available from: https://doi.org/10.3389/fphar.2023.1218015

[16] Boronat A, Rodríguez-Morató J, Serreli G, Fitó M, Tyndale RF, Deiana M, Torre R de la. Contribution of Biotransformations Carried Out by the Microbiota, Drug-Metabolizing Enzymes, and Transport Proteins to the Biological Activities of Phytochemicals Found in the Diet. Advances in Nutrition [Internet]. Elsevier BV; 2021 Aug 9 [cited 2025 Feb];12(6):2172. Available from: https://doi.org/10.1093/advances/nmab085

[17] Casanova E, Salvadó MJ, Crescenti A, Gibert-Ramos A. Epigallocatechin Gallate Modulates Muscle Homeostasis in Type 2 Diabetes and Obesity by Targeting Energetic and Redox Pathways: A Narrative Review. International Journal of Molecular Sciences [Internet]. Multidisciplinary Digital Publishing Institute; 2019 Jan 27 [cited 2025 Apr];20(3):532. Available from: https://doi.org/10.3390/ijms20030532

[18] Hengge R. Targeting Bacterial Biofilms by the Green Tea Polyphenol EGCG. Molecules [Internet]. Multidisciplinary Digital Publishing Institute; 2019 Jun 29 [cited 2025 Apr];24(13):2403. Available from: https://doi.org/10.3390/molecules24132403

[19] Sørensen JC, Frandsen HB, Jensen SK, Kristensen NB, Sørensen S, Sørensen H. Bioavailability and in vivo metabolism of intact glucosinolates. Journal of Functional Foods [Internet]. 2016 May 7 [cited 2025 Feb];24:450. Available from: https://doi.org/10.1016/j.jff.2016.04.023

[20] Chang-Chen KJ, Mullur R, Bernal-Mizrachi E. β-cell failure as a complication of diabetes. Reviews in Endocrine and Metabolic Disorders [Internet]. Springer Science+Business Media; 2008 Sep 6 [cited 2025 Apr];9(4):329. Available from: https://doi.org/10.1007/s11154-008-9101-5

[21] Veeraveedu PT, Ramamurthy S, Kumar A, Gupta M, Bansal G. Protective role of epigallocatechin gallate, a dietary antioxidant against oxidative stress in various diseases. In: Pathology [Internet]. 2020 [cited 2025 Mar]. p. 213. Available from: https://doi.org/10.1016/b978-0-12-815972-9.00021-4

[22] Hardie DG, Ashford MLJ. AMPK: Regulating Energy Balance at the Cellular and Whole Body Levels. Physiology [Internet]. American Physiological Society; 2014 Mar 1 [cited 2025 Feb];29(2):99. Available from: https://doi.org/10.1152/physiol.00050.2013

[23] Zhang ZF, Li Q, Liang J, Dai X, Ding Y, Wang JB, Li Y. Epigallocatechin-3-O-gallate (EGCG) protects the insulin sensitivity in rat L6 muscle cells exposed to dexamethasone condition. Phytomedicine [Internet]. 2009 Oct 13 [cited 2025 Apr];17(1):14. Available from: https://doi.org/10.1016/j.phymed.2009.09.007

[24] Li W, Zhu C, Liu T, Zhang W, Liu X, Li P, Zhu T. Epigallocatechin-3-gallate ameliorates glucolipid metabolism and oxidative stress in type 2 diabetic rats. Diabetes and Vascular Disease Research [Internet]. 2020 Nov 1 [cited 2025 Apr];17(6). Available from: https://doi.org/10.1177/1479164120966998

[25] Keske MA, Ng H, Premilovac D, Rattigan S, Kim J, Munir KM, Yang P, Quon MJ. Vascular and Metabolic Actions of the Green Tea Polyphenol Epigallocatechin Gallate. Current Medicinal Chemistry [Internet]. Bentham Science Publishers; 2014 Oct 15 [cited 2025 Mar];22(1):59. Available from: https://doi.org/10.2174/09298673216661410121745 53

[26] Jang HJ, Ridgeway SD, Kim J. Effects of the green tea polyphenol epigallocatechin-3-gallate on high-fat diet-induced insulin resistance and endothelial dysfunction. AJP Endocrinology and Metabolism [Internet]. 2013 Oct 23 [cited 2025 Apr];305(12). Available from: https://doi.org/10.1152/ajpendo.00434.2013

[27] Gill V, Kumar V, Singh K, Kumar A, Kim JJ. Advanced Glycation End Products (AGEs) May Be a Striking Link Between Modern Diet and Health. Biomolecules [Internet]. Multidisciplinary Digital Publishing Institute; 2019 Dec 17 [cited 2025 Apr];9(12):888. Available from: https://doi.org/10.3390/biom9120888

[28] Collins QF, Liu HY, Pi J, Liu Z, Quon MJ, Cao W. Epigallocatechin-3-gallate (EGCG), A Green Tea Polyphenol, Suppresses Hepatic Gluconeogenesis through 5′-AMP-activated Protein Kinase. Journal of Biological Chemistry [Internet]. 2007 Aug 28 [cited 2025 Apr];282(41):30143. Available from: https://doi.org/10.1074/jbc.m702390200

[29] Walum E. Acute oral toxicity. Environmental Health Perspectives [Internet]. 1998 Apr 1 [cited 2025 Feb];106:497. Available from: https://doi.org/10.1289/ehp.98106497

[30] Roghani M, Baluchnejadmojarad T. Hypoglycemic and hypolipidemic effect and antioxidant activity of chronic epigallocatechin-gallate in streptozotocin-diabetic rats. Pathophysiology [Internet]. 2009 Aug 14 [cited 2025 Apr];17(1):55. Available from: https://doi.org/10.1016/j.pathophys.2009.07.004

[31] Sampath C, Rashid MR, Sang S, Ahmedna M. Green tea epigallocatechin 3-gallate alleviates hyperglycemia and reduces advanced glycation end products via nrf2 pathway in mice with high fat diet-induced obesity. Biomedicine & Pharmacotherapy [Internet]. 2016 Dec 29 [cited 2025 Apr];87:73. Available from: https://doi.org/10.1016/j.biopha.2016.12.082

[32] Wang X, Liu H, Chen J, Li Y, Qu S. Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1.

International Journal of Endocrinology [Internet]. Hindawi Publishing Corporation; 2015 Jan 1 [cited 2025 Mar];2015:1. Available from: https://doi.org/10.1155/2015/651757

[33] Zhu T, Li M, Zhu M, Liu X, Huang K, Li W, Wang S, Yin Y, Li P. Epigallocatechin-3-gallate alleviates type 2 diabetes mellitus via β-cell function improvement and insulin resistance reduction. DOAJ (DOAJ: Directory of Open Access Journals) [Internet]. 2022 Apr 1 [cited 2025 Mar];25(4):483. Available from: https://doaj.org/article/7db9e07204ba41bfb0f49f8f73b1da7d

[34] Hayashi A, Terasaka S, Nukada Y, Kameyama A, Yamane M, Shioi R, Iwashita M, Hashizume K, Morita O. 4″-Sulfation Is the Major Metabolic Pathway of Epigallocatechin-3-gallate in Humans: Characterization of Metabolites, Enzymatic Analysis, and Pharmacokinetic Profiling. Journal of Agricultural and Food Chemistry [Internet]. 2022 Jul 5 [cited 2025 Apr];70(27):8264. Available from: https://doi.org/10.1021/acs.jafc.2c02150

[35] Bazyar H, Hosseini SA, Saradar S, Mombaini D, Allivand M, Labibzadeh M, Alipour M. Effects of epigallocatechin-3-gallate of Camellia sinensis leaves on blood pressure, lipid profile, atherogenic index of plasma and some inflammatory and antioxidant markers in type 2 diabetes mellitus patients: a clinical trial. Journal of Complementary and Integrative Medicine [Internet]. 2020 Dec 25 [cited 2025 Apr];18(2):405. Available from: https://doi.org/10.1515/jcim-2020-0090

[36] . Hadi S, Alipour M, Aghamohammadi V, Shahemi S, Taleghani F, Pourjavidi N, Foroughi M, Chraqipoor M. Improvement in fasting blood sugar, anthropometric measurement and hs-CRP after consumption of epigallocatechin-3-gallate (EGCG) in patients with type 2 diabetes mellitus. Nutrition & Food Science [Internet]. 2019 Aug 16 [cited 2025 Apr];50(2):348. Available from: https://doi.org/10.1108/nfs-04-2019-0126

[37] Gao J, Xu P, Wang Y, Wang Y, Hochstetter D. Combined Effects of Green Tea Extracts, Green Tea Polyphenols or Epigallocatechin Gallate with Acarbose on Inhibition against α-Amylase and α-Glucosidase in Vitro. Molecules [Internet]. 2013 Sep 18 [cited 2025 Apr];18(9):11614. Available from: https://doi.org/10.3390/molecules180911614

[38] Zhang G, Zhang J. Enhanced oral bioavailability of EGCG using pH-sensitive polymeric nanoparticles: characterization and in vivo investigation on nephrotic syndrome rats. Drug Design Development and Therapy [Internet]. 2018 Aug 1 [cited 2025 Mar];2509. Available from: https://doi.org/10.2147/dddt.s172919